
Raphael Hirsch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5876449/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MR imaging of murine arthritis using ultrasmall superparamagnetic iron oxide particlesâ~†. Magnetic Resonance Imaging, 2001, 19, 1209-1216.	1.8	348
2	NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. Journal of Experimental Medicine, 2006, 203, 1209-1219.	8.5	173
3	Kawasaki Disease. Pediatric Clinics of North America, 1995, 42, 1205-1222.	1.8	119
4	Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis and Rheumatism, 1999, 42, 1109-1118.	6.7	117
5	ANTI-CD3 F(ab')2 FRAGMENTS ARE IMMUNOSUPPRESSIVE IN VIVO WITHOUT EVOKING EITHER THE STRONG HUMORAL RESPONSE OR MORBIDITY ASSOCIATED WITH WHOLE mAb. Transplantation, 1990, 49, 1117-1123.	1.0	110
6	Follistatin-Like Protein-1 Is a Novel Proinflammatory Molecule. Journal of Immunology, 2006, 177, 4758-4762.	0.8	107
7	Adeno-Associated Virus Mediates Long-Term Gene Transfer and Delivery of Chondroprotective IL-4 to Murine Synovium. Molecular Therapy, 2000, 2, 147-152.	8.2	96
8	Viral IL-10 and Soluble TNF Receptor Act Synergistically to Inhibit Collagen-Induced Arthritis Following Adenovirus- Mediated Gene Transfer. Journal of Immunology, 2000, 164, 1576-1581.	0.8	89
9	Follistatin-Like Protein 1 Promotes Arthritis by Up-Regulating IFN-γ. Journal of Immunology, 2009, 182, 234-239.	0.8	88
10	Follistatin-like protein 1 and its role in inflammation and inflammatory diseases. Immunologic Research, 2014, 59, 266-272.	2.9	86
11	Anti-T Cell Receptor Monoclonal Antibody Prolongs Transgene Expression Following Adenovirus-Mediated In Vivo Gene Transfer to Mouse Synovium. Human Gene Therapy, 1996, 7, 499-506.	2.7	83
12	Safety of Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA to the Lungs of Nonhuman Primates. Human Gene Therapy, 1996, 7, 301-318.	2.7	79
13	DNA Microarray Analysis Reveals Novel Gene Expression Profiles in Collagen-Induced Arthritis. Clinical Immunology, 2002, 105, 155-168.	3.2	69
14	Follistatinâ€like protein 1 is a mesenchymeâ€derived inflammatory protein and may represent a biomarker for systemicâ€onset juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 2510-2516.	6.7	69
15	Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis and Rheumatism, 1998, 41, 1798-1805.	6.7	68
16	Adenovirus-Mediated Granulocyte-Macrophage Colony-Stimulating Factor Improves Lung Pathology of Pulmonary Alveolar Proteinosis in Granulocyte-Macrophage Colony-Stimulating Factor-Deficient Mice. Human Gene Therapy, 1998, 9, 2101-2109.	2.7	63
17	Three-dimensional and thermal surface imaging produces reliable measures of joint shape and temperature: a potential tool for quantifying arthritis. Arthritis Research and Therapy, 2008, 10, R10.	3.5	61
18	FSTL1 promotes arthritis in mice by enhancing inflammatory cytokine/chemokine expression. Arthritis and Rheumatism. 2012, 64, 1082-1088.	6.7	60

RAPHAEL HIRSCH

#	Article	IF	CITATIONS
19	Proteasome Inhibition Enhances AAV-Mediated Transgene Expression in Human Synoviocytes in Vitro and in Vivo. Molecular Therapy, 2005, 11, 600-607.	8.2	55
20	Akt Fine-tunes NF-κB-dependent Gene Expression during T Cell Activation. Journal of Biological Chemistry, 2011, 286, 36076-36085.	3.4	52
21	Follistatin-like Protein 1 and the Ferritin/Erythrocyte Sedimentation Rate Ratio Are Potential Biomarkers for Dysregulated Gene Expression and Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2013, 40, 1191-1199.	2.0	51
22	Follistatinâ€like protein 1 enhances NLRP3 inflammasomeâ€mediated ILâ€1β secretion from monocytes and macrophages. European Journal of Immunology, 2014, 44, 1467-1479.	2.9	48
23	Heterogeneous Effects of IL-2 on Collagen-Induced Arthritis. Journal of Immunology, 2000, 165, 1557-1563.	0.8	47
24	T-cell and T-cell receptor abnormalities in the immunopathogenesis of juvenile rheumatoid arthritis. Current Opinion in Rheumatology, 2000, 12, 420-424.	4.3	45
25	Toxoplasmosis in bone marrow transplant recipients. Journal of Pediatrics, 1984, 105, 426-428.	1.8	39
26	Follistatin-like protein 1 regulates chondrocyte proliferation and chondrogenic differentiation of mesenchymal stem cells. Annals of the Rheumatic Diseases, 2015, 74, 1467-1473.	0.9	39
27	Expression of angiogenic factors in juvenile rheumatoid arthritis: Correlation with revascularization of human synovium engrafted into SCID mice. Arthritis and Rheumatism, 2001, 44, 794-801.	6.7	38
28	Synovial fluid proteins differentiate between the subtypes of juvenile idiopathic arthritis. Arthritis and Rheumatism, 2010, 62, 1813-1823.	6.7	34
29	Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging?. Arthritis Care and Research, 2012, 64, 1846-1854.	3.4	32
30	Plasma Follistatin-Like Protein 1 is Elevated in Kawasaki Disease and May Predict Coronary Artery Aneurysm Formation. Journal of Pediatrics, 2012, 161, 116-119.	1.8	26
31	A Single-Chain Class II MHC-IgG3 Fusion Protein Inhibits Autoimmune Arthritis by Induction of Antigen-Specific Hyporesponsiveness. Journal of Immunology, 2002, 168, 2554-2559.	0.8	25
32	Anti-T Cell Receptor Antibody Prolongs Transgene Expression and Reduces Lung Inflammation after Adenovirus-Mediated Gene Transfer. Human Gene Therapy, 1997, 8, 935-941.	2.7	24
33	NK cells secrete high levels of IFN- $\hat{1}^3$ in response toin vivo administration of IL-2. European Journal of Immunology, 2001, 31, 3355-3360.	2.9	19
34	COMPARISON OF IN VIVO EFFICACY AND MECHANISM OF ACTION OF ANTIMURINE MONOCLONAL ANTIBODIES DIRECTED AGAINST TCR αβ (H57–597) AND CD3 (145–2C11). Transplantation, 1995, 60, 828	-8 3 5.	18
35	Reduction of mortality and lymphadenopathy in mrl-lpr/lpr mice treated with nonmitogenic anti-cd3 monoclonal antibody. Arthritis and Rheumatism, 1994, 37, 587-594.	6.7	16
36	Gene transfer of a fibronectin peptide inhibits leukocyte recruitment and suppresses inflammation in mouse collagen-induced arthritis. Arthritis and Rheumatism, 2002, 46, 1102-1108.	6.7	16

RAPHAEL HIRSCH

#	Article	IF	CITATIONS
37	Hypocomplementemia Associated with Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still's Disease: 3 Cases: Table 1 Journal of Rheumatology, 2011, 38, 396-397.	2.0	16
38	On the Mechanism of Protection of Distal Joints after Local Gene Transfer in Collagen-Induced Arthritis. Human Gene Therapy, 2000, 11, 751-758.	2.7	15
39	Inflammatory cytokine regulation of transgene expression in human fibroblast-like synoviocytes infected with adeno-associated virus. Arthritis and Rheumatism, 2006, 54, 2119-2126.	6.7	15
40	Gene therapy for arthritis. Modern Rheumatology, 2008, 18, 2-14.	1.8	13
41	Pediatric Pigmented Villonodular Synovitis Mimicking a Septic Hip. Journal of Clinical Rheumatology, 2010, 16, 71-73.	0.9	12
42	Gene therapy for arthritis. Modern Rheumatology, 2008, 18, 2-14.	1.8	12
43	A Divalent Major Histocompatibility Complex/IgG1 Fusion Protein Induces Antigen-Specific T Cell Activationin Vitroandin Vivo. Cellular Immunology, 1999, 192, 54-62.	3.0	11
44	Staphylococcus aureus Panniculitis Complicating Juvenile Dermatomyositis. Pediatrics, 2007, 119, e528-e530.	2.1	11
45	Follistatinâ€like protein 1 modulates ILâ€17 signaling via ILâ€17RC regulation in stromal cells. Immunology and Cell Biology, 2017, 95, 656-665.	2.3	11
46	FSTL-1 Attenuation Causes Spontaneous Smoke-Resistant Pulmonary Emphysema. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 934-945.	5.6	11
47	Recombinant adeno-associated virus preferentially transduces human, compared to mouse, synovium: implications for arthritis therapy. Modern Rheumatology, 2004, 14, 18-24.	1.8	9
48	Recombinant adeno-associated virus preferentially transduces human, compared to mouse, synovium: implications for arthritis therapy. Modern Rheumatology, 2004, 14, 18-24.	1.8	9
49	Suppression of arthritis-induced bone erosion by a CRAC channel antagonist. RMD Open, 2016, 2, e000093.	3.8	8
50	ANTI-CD3 ANTIBODY FOR AUTOIMMUNE DISEASE, A CAUTIONARY NOTE. Lancet, The, 1989, 333, 1390.	13.7	7
51	A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo. Clinical Immunology, 2005, 116, 65-76.	3.2	7
52	The Follistatinâ€like Protein 1 Pathway Is Important for Maintaining Healthy Articular Cartilage. ACR Open Rheumatology, 2020, 2, 407-414.	2.1	7
53	CONTRASTING IN VIVO EFFECTS ON T HELPER CELL FUNCTIONS INDUCED BY MITOGENIC (INTACT) VERSUS		

RAPHAEL HIRSCH

#	Article	IF	CITATIONS
55	Follistatin-like protein 1 is a critical mediator of experimental Lyme arthritis and the humoral response to Borrelia burgdorferi infection. Microbial Pathogenesis, 2014, 73, 70-79.	2.9	6
56	Pediatric rheumatology workforce: a status update. Current Opinion in Rheumatology, 2004, 16, 553-554.	4.3	4
57	T helper 2 (Th2) but not Th1 clones costimulate resting T cells in the presence of anti-CD3 monoclonal antibody. International Immunology, 1989, 1, 443-449.	4.0	3
58	Pediatric rheumatology: a call to action. Current Opinion in Rheumatology, 2003, 15, 571.	4.3	2
59	Regulation of Pulmonary Bacterial Immunity by Follistatin-Like Protein 1. Infection and Immunity, 2020, 89, .	2.2	2
60	Immunopotentiation of Anti-Viral and Anti-Tumor Immune Responses Using Anti-T Cell Receptor Antibodies and Mitogens. Annals of the New York Academy of Sciences, 1991, 636, 279-287.	3.8	1
61	Gene therapy for rheumatoid arthritis. Future Rheumatology, 2007, 2, 403-413.	0.2	1
62	Anti-CD3 therapy enhances hematopoiesis and blocks graft-versus-host disease. International Journal of Cell Cloning, 1991, 9, 91-104.	1.6	0
63	Osteonecrosis of the Femoral Head after Acute Rheumatic Fever. Journal of Clinical Rheumatology, 2000, 6, 321-323.	0.9	0
64	ls long-term etanercept therapy safe and effective in patients with juvenile RA?. Nature Clinical Practice Rheumatology, 2008, 4, 628-629.	3.2	0